These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7461027)

  • 1. Comparison of the serum protein binding of maprotiline and phenytoin in uraemic patients on haemodialysis.
    Lynn K; Braithwaite R; Dawling S; Rosser R
    Eur J Clin Pharmacol; 1981 Jan; 19(1):73-7. PubMed ID: 7461027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.
    Oellerich M; Müller-Vahl H
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():61-70. PubMed ID: 6705428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenytoin protein binding and dosage requirements during acute and convalescent phases following brain injury.
    Markowsky SJ; Skaar DJ; Christie JM; Eyer SD; Ehresman DJ
    Ann Pharmacother; 1996 May; 30(5):443-8. PubMed ID: 8740320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.
    Odar-Cederlöf I; Borga O
    Clin Pharmacol Ther; 1976 Jul; 20(1):36-47. PubMed ID: 1277724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients.
    Ehrnebo M; Odar-Cederlöf I
    Eur J Clin Pharmacol; 1975 Aug; 8(6):445-53. PubMed ID: 1233247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.
    Odar-Cederlöf I; Borgå O
    Eur J Clin Pharmacol; 1974; 7(1):31-7. PubMed ID: 4852619
    [No Abstract]   [Full Text] [Related]  

  • 7. Alterations of phenytoin protein binding with in vivo haemodialysis in dialysis encephalopathy.
    Steele WH; Lawrence JR; Elliott HL; Whiting B
    Eur J Clin Pharmacol; 1979 Feb; 15(1):69-71. PubMed ID: 421730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of antipyrine, phenylbutazone and phenytoin in experimental renal failure.
    Van Peer AP; Belpaire FM; Rosseel MT; Bogaert MG
    Pharmacology; 1981; 22(2):139-45. PubMed ID: 7208595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of maprotiline intravenous kinetics and comparison of two oral doses.
    Maguire KP; Norman TR; Burrows GD; Scoggins BA
    Eur J Clin Pharmacol; 1980 Oct; 18(3):249-54. PubMed ID: 7439244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation and prediction of phenytoin protein binding using standard laboratory parameters in patients after renal transplantation.
    Monaghan MS; Marx MA; Olsen KM; Turner PD; Bergman KL
    Ther Drug Monit; 2001 Jun; 23(3):263-7. PubMed ID: 11360036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metabolic fate of [14C]oxaprotiline.HCl in man. I. Disposition and preliminary pharmacokinetics.
    Dieterle W; Faigle JW; Imhof P; Sulc M; Wagner J
    Xenobiotica; 1984 Apr; 14(4):303-10. PubMed ID: 6464500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation.
    Odar-Cederlof I
    Clin Pharmacokinet; 1977; 2(2):147-53. PubMed ID: 324689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy.
    Barth N; Alván G; Borgå O; Sjöqvist F
    Clin Pharmacokinet; 1976; 1(6):444-52. PubMed ID: 1024769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma protein binding of phenytoin in 100 epileptic patients.
    Peterson GM; McLean S; Aldous S; Von Witt RJ; Millingen KS
    Br J Clin Pharmacol; 1982 Aug; 14(2):298-300. PubMed ID: 7104186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenytoin binding in healthy volunteers.
    Berg MJ; Ebert BE; Fincham RW; Schottelius DD
    Ther Drug Monit; 1987 Dec; 9(4):384-8. PubMed ID: 3424404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds.
    Dasgupta A; Abu-Alfa A
    Am J Clin Pathol; 1992 Jul; 98(1):19-25. PubMed ID: 1615921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.
    Reidenberg MM; Odar-Cederlöf I; von Bahr C; Borgå O; Sjöqvist F
    N Engl J Med; 1971 Jul; 285(5):264-7. PubMed ID: 4378402
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioavailability and kinetics of maprotiline.
    Alkalay D; Wagner WE; Carlsen S; Khemani L; Volk J; Bartlett MF; LeSher A
    Clin Pharmacol Ther; 1980 May; 27(5):697-703. PubMed ID: 7371367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat inhibition of in vitro lipolysis and 14C ibuprofen protein binding in plasma from heparinized uraemic subjects.
    Pearce GA; Brown KF
    Life Sci; 1983 Oct; 33(15):1457-66. PubMed ID: 6621250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly.
    Hrdina PD; Rovei V; Henry JF; Hervy MP; Gomeni R; Forette F; Morselli PL
    Psychopharmacology (Berl); 1980; 70(1):29-34. PubMed ID: 6775331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.